Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25503 | 1.00 | RECQL (0.44) | RECQLMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL10061890 | 0.93 | RECQL (0.50) | RECQLMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL25501 | 0.91 | RECQL (0.45) | RECQLMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL636942 | 0.88 | MEN1 (0.40) | RECQLMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL24993 | 0.88 | MEN1 (0.40) | RECQLMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL7680649 | 0.87 | RECQL (0.43) | RECQLMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL25823 | 0.86 | CYSLTR2 (0.41) | MEN1KMT2ASMN1; SMN2LMNACYSLTR2 | |
| SCHEMBL25822 | 0.86 | CYSLTR2 (0.41) | MEN1KMT2ASMN1; SMN2LMNACYSLTR2 | |
| SCHEMBL24651 | 0.85 | LMNA (0.43) | RECQLMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL24652 | 0.85 | LMNA (0.43) | RECQLMEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160090353-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-9238616-B2 | Prodrugs of gaba analogs, compositions and uses thereof | XENOPORT, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20150307442-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | ARBOR PHARMACEUTICALS, LLC | 2015-10-29 | — | — | US | disclosed |
| US-20130102641-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8367722-B2 | Methods of using prodrugs of pregabalin | XENOPORT, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8168623-B2 | Prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20120035258-A1 | METHODS OF USING PRODRUGS OF PREGABALIN | XENOPORT, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| EP-1902714-B1 | Prodrugs of gaba analogs, compositions and uses thereof | XENOPORT INC (US) | 2012-01-11 | — | — | EP | disclosed |
| US-8048917-B2 | Prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| EP-1404324-B2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2011-04-06 | — | — | EP | disclosed |
| US-6472397-B1 | Nitrogen-containing heterocyclic compounds having antiplatelet aggregation effect and medicinal use thereof | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-10-29 | — | — | US | disclosed |
| EP-1242059-A2 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020019437-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-02-14 | — | — | US | disclosed |
| EP-0800516-B1 | FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED (b)-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON STEEL CORP (JP) | 2001-09-19 | — | — | EP | disclosed |
| EP-1070712-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING ANTIPLATELET AGGREGATION EFFECT AND MEDICINAL USE THEREOF | MEIJI SEIKA KAISHA LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
| WO-2001003685-A2 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2001-01-18 | — | — | WO | disclosed |
| US-5866592-A | Fibrinogen receptor antagonist and pharmaceutical compositions comprising the same | NIPPON STEEL CORPORATION (JP) | 1999-02-02 | — | — | US | disclosed |
| EP-0800516-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED (b)-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON STEEL CORPORATION (JP) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020172-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED β-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON STEEL CORPORATION (JP) | 1996-07-04 | — | — | WO | disclosed |
| US-4994484-A | 1-(3-(2-hydroxy-3-alkylaminopropoxy)-2-thienyl)-3-phenyl-1-propanones and process for the preparation of the same | LAEVOSAN-GESELLSCHAFT M.B.H. (AT) | 1991-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090353-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | RECQL 4166/4885MEN1 2201/4885KMT2A 2132/4885 |
| US-20150307442-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | RECQL 4166/4885MEN1 2201/4885KMT2A 2132/4885 |
| US-20120035258-A1 | METHODS OF USING PRODRUGS OF PREGABALIN | GABBR1, GABRB2, GABBR2 | RECQL 3609/4885MEN1 2599/4885KMT2A 2790/4885 |
| US-20130102641-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | RECQL 4166/4885MEN1 2201/4885KMT2A 2132/4885 |
| US-20020019437-A1 | Novel prodrugs for antimicrobial amidines | NR1H3, APEH, NR1H2 | RECQL 1243/4885MEN1 4773/4885KMT2A 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.